Absence of Detectable XMRV and Other MLV-Related Viruses in Healthy Blood Donors in the United States by Tang, Shixing et al.
Absence of Detectable XMRV and Other MLV-Related
Viruses in Healthy Blood Donors in the United States
Shixing Tang*, Jiangqin Zhao, Mohan Kumar Haleyur Giri Setty, Krishnakumar Devadas, Durga Gaddam,
Ragupathy Viswanath, Owen Wood, Panhe Zhang, Indira K. Hewlett*
Lab of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
Abstract
Background: Preliminary studies in chronic fatigue syndrome (CFS) patients and XMRV infected animals demonstrated
plasma viremia and infection of blood cells with XMRV, indicating the potential risk for transfusion transmission. XMRV and
MLV-related virus gene sequences have also been detected in 4–6% of healthy individuals including blood donors in the
U.S. These results imply that millions of persons in the U.S. may be carrying the nucleic acid sequences of XMRV and/or MLV-
related viruses, which is a serious public health and blood safety concern.
Methodology/Principal Findings: To gain evidence of XMRV or MLV-related virus infection in the U.S. blood donors, 110
plasma samples and 71 PBMC samples from blood donors at the NIH blood bank were screened for XMRV and MLV-related
virus infection. We employed highly sensitive assays, including nested PCR and real-time PCR, as well as co-culture of plasma
with highly sensitive indicator DERSE cells. Using these assays, none of the samples were positive for XMRV or MLV-related
virus.
Conclusions/Significance: Our results are consistent with those from several other studies, and demonstrate the absence of
XMRV or MLV-related viruses in the U.S. blood donors that we studied.
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Introduction
Xenotropic murine leukemia virus-related virus (XMRV) was
originally identified in prostate cancer tissues in 2006 [1], and
proposed to be associated with PC [1,2,3,4,5] and chronic fatigue
syndrome (CFS) [6,7]. However, a causal relationship has not
been validated and several controversial findings have been
reported [8,9,10,11,12]. Furthermore, XMRV as a human
pathogen has been questioned since mouse DNA contamination
has been found in human samples tested [13,14,15,16], and
XMRV may be the result of a recombination of two MLV
ancestors [17]. As a newly identified retrovirus, XMRV can infect
human tissues and cells including lymphoid organs [18] and
peripheral blood mononuclear cells (PBMCs) [6], indicating
potential transfusion transmission of XMRV. XMRV has also
been detected in 3.7% of healthy individuals [6] and 5.9% of non-
prostate cancer patients [2] in the U.S.. In addition, Lo et al
reported that 6.8% of U.S. healthy blood donors carried MLV-
related sequences, which are molecularly different from but very
similar to XMRV [19]. These results, if confirmed, imply that
millions of persons in the U.S. may harbor XMRV and/or MLV-
related viruses and thus pose a serious threat to public health,
including blood safety and organ transplantation. To ensure blood
safety, suggestions and preventive measures have been proposed,
such as developing screening tools and deferring CFS patients for
blood donation [20]. However, these recommendations and
measures have been questioned in the absence of the conclusive
consensus of the prevalence of XMRV infection in blood donors
and causality for human diseases. In order to address blood safety
concerns, the Blood XMRV Scientific Research Working Group
(SRWG) composed of members from academia, government and
blood organizations was formed by the National Heart, Lung, and
Blood Institute (NHLBI) [21]. The major goals of this group were
to 1) validate the testing methods for XMRV since one of the
possible reasons for the conflicting findings was attributed to
differences in testing methods, and 2) to investigate possible
infection of blood donors with XMRV or MLV-related viruses.
During the past two years, our laboratory actively participated
in assay validation and assessment of the threats posed by XMRV
on blood safety. We previously reported that our RT-PCR assay
could detect 10 copies and 1 copy of plasmid DNA in the 1
st and
2
nd round PCR, respectively [22] by using primers described by
Silverman et al [1] and Mikovits et al [6]. Our quantitative PCR
assay could detect 1–10 copies of XMRV plasmid DNA, which is
comparable to the results reported by Schlaberg et al [2]. Our
PCR assays were able to achieve similar levels of sensitivity and
specificity based on the spiked XMRV panels created by the Blood
XMRV SRWG [21]. For virus culture, we set up an infectivity
assay using the Detectors of Exogenous Retroviral Sequence
Elements (DERSE) indicator cells where plasma samples are co-
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XMRV infection and virus replication monitored using a
fluorescence signal [23]. Mikovits et al who reported the
association of XMRV with CFS claimed that culture of virus
from plasma was the most sensitive blood-based assay for detection
of XMRV [7]. By using these highly sensitive assays, we screened
U.S. blood donors for XMRV or MLV-related viruses in order to
provide further evidence of the status of these possible new viruses
in the blood donors from the NIH Blood Bank, the same blood
bank from which donors had previously reported to harbor
polytropic MLV-related virus sequences in 6.8% of the individuals
tested [19].
Materials and Methods
Ethics Statement
The Food and Drug Administration Research Ethics Commit-
tee has waived the need for consent due to the fact the blood donor
material used was fully anonymised.
Collection and PCR testing
A total of 71 PMBC samples and 110 plasma samples from
blood donors were enrolled in our study. Both plasma and PBMCs
were recovered from the entire buffy coat that was received from
the NIH Blood Bank. Briefly, the entire buffy coat was centrifuged
at 1500 rpm for 15 minutes and plasma was carefully removed.
Cells were resuspended in 15 ml of Ficoll solution and centrifuged
for 30 minutes at 400g. The PBMCs, seen as a ring or band at the
top of the Ficoll solution, were removed, placed in a fresh 50 ml
tube and filled with PBS saline for further use.
Viral RNA was extracted from 140 ml of plasma using QIAamp
MiniElute Virus Spin kit (Qiagen, Valencia, CA), and genomic
DNA of 1610
6 PBMCs was extracted using the QIAamp DNA
Blood mini kit. Reverse transcription was performed with
SuperScript III for First-strand Synthesis System (Invitrogen)
using 8 ul of viral RNA or total nucleic acid from PBMC and
XMRV gag reverse primer 1154R [6]. For amplification of
XMRV gag gene, first-round PCR was performed in a 20 ul
volume containing 5 ul of cDNA or 200,500 ng of genomic
DNA, 10 ul of 2xPCR buffer (Extensor Hi-Fidelity ReddyMix
PCR Master Mix, ABgen House, Surrey, UK) and 2.5 pmol each
primer (GAG-O-F and GAG-O-R) [1]. Reaction conditions were
one cycle at 94uC, 59, 45 cycles at 94uC, 19,5 8 uC,1 9,7 2 uC, 19
and one cycle at 72uC, 79. Two microliters of 1
st round PCR
products were added to 2
nd round PCR with the same reaction
conditions as those in the 1
st PCR except that the different primers
(GAG-I-F and GAG-I-R) and the annealing temperature of 60uC
were used [1]. Each PCR run included both XMRV positive
control (a full-length XMRV plasmid DNA, isolate VP62, gifted
by Dr R. Silverman) and negative control (water). PCR
amplification products were visualized on a 2% agarose gel
stained with ethidium bromide. Each sample was tested in
triplicate, the band equivalent to the correct size of positive
control was excised from 2% agarose gel using the QIAquick gel
extraction kit (Qiagen Inc., Valencia, CA) for sequence analysis.
Alternatively, a specific PCR product was purified using ExoSAP-
IT reagent (usb, Santa Clara, CA). Purified PCR products were
sequenced directly using the ABI Prism BigDye Terminator Cycle
Sequencing kit in the ABI PRISM 310 Genetic Analyzer (Applied
Biosystems, Foster City, CA). Sequence and phylogenetic analyses
were performed using the MEGA5 software package and the
Invitrogen Vector NTI software, version 11.3.0 (Invitrogen,
Carlsbad, CA). A positive test result was defined as one where at
least one band of the correct size was detected in triplicate PCR
reactions, and confirmed by sequencing as XMRV. A negative
result was defined as one where no bands of the correct size were
detected in triplicate PCR reactions or at least one band of correct
size was observed but the sequence analysis did not confirm as
XMRV. To ensure integrity of extracted DNAs, human GAPDH
gene was amplified with the same PCR primers (hGAPDH-66F
and hGAPDH-291R) and conditions published previously [1]. To
avoid possible mouse DNA contamination, PCR assays for
amplifying mouse intracisternal A particle (IAP), mouse mito-
chondrial DNA were performed as previously described
[13,15,19]. The experiments were performed by two laboratory
personnel to ensure that results were scored based on reproduc-
ibility of data obtained by two independent operators.
Cell culture assay for detection of infectious virus
A co-culture assay was adopted to monitor XMRV infection by
using Detectors of Exogenous Retroviral Sequence Elements
(DERSE) cells that are LNCaP-iGFP cell clones displaying
sensitivity to XMRV infection that leads to expression of a GFP
reporter [23]. In this assay, a derivative of LNCaP cells termed
DERSE.LiGP cells (a gift from Dr Vineet KewalRamani, NCI)
were used. DERSE cells were selected to express pBabe.iGFP-
puro, a MLV proviral vector encoding an intron-interrupted GFP
reporter gene. In this indicator cell line, GFP is only expressed
after mobilization by an infecting gammaretrovirus during a
second round of infection. Briefly, 0.4610
5 DERSE cells/well
were added in 24-well plate. After 24–48 hours, the cells were
mixed with 200 ul of plasma samples or normal plasma spiked
with XMRV. The plate was centrifuged at 1500 rpm (Eppendorf
Centrifuge # 5810 R) for 5 minutes, and then incubated at 37uC
overnight. Plasma was very carefully replaced with fresh RPMI
complete media, and transferred to a 6-well plate to expand as
required (usually after 4–5 days post infection). When cells became
confluent, they were transferred to a T-25 flask and maintained for
21 days post infection. GFP expression in cells at different days
post-infection was determined using fluorescence microscopy.
Results
By using serial 1:10 dilutions of XMRV plasmid DNA with
known copy numbers based on absorbance A260 of the purified
plasmid VP62, 10 copies and one copy of plasmid DNA were
detected in the first- and second-round PCR, a lower detection
limit of one copy of proviral DNA using our current nested PCR
conditions was achieved. The sensitivity of the PCR assays was
also evaluated using XMRV DNA extracted from a series of 1:10
dilutions of 22Rv1 cells (CRL-2505, ATCC, Gaithersburg, MD)
that harbor multiple copies of integrated XMRV provirus and
constitutively produce infectious virus [24]. The current nested
PCR assay could detect XMRV DNA from single 22Rv1 cells
(data not shown). Using this assay, none of the 110 plasma samples
were positive for XMRV or MLV-related virus with either
XMRV gag primer sets although the positive control was
successfully amplified in each PCR run (Fig. 1A). Total nucleic
acid from 71 PBMC samples was also tested but found to be
negative for XMRV or MLV-related virus using both nested DNA
PCR and RT-PCR assays (Fig. 1B, Table 1). Both assays were
used since it was reported that RT-PCR could be more sensitive
than DNA PCR for detection of XMRV in activated PBMCs [7].
Any bands with similar size of XMRV positive control were
excised from the gel, purified and sequenced. No XMRV
sequences were found on sequence analysis. A specific hGAPDH
gene was amplified from all 71 PBMC samples (Fig. 1C),
indicating the integrity of the extracted DNA.
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three days of XMRV infection, with the number of GFP-positive
cells increasing over subsequent days. The DERSE GFP culture
method is highly sensitive as it can detect around 2000 copies of
XMRV. In our study, DERSE cells could be successfully infected
by culture supernatant of the 22Rv1 cell line which carries XMRV
[24] (Fig. 2A) and displayed fluorescence 4 days after infection
(Fig. 2B). GFP expression was observed 18 days post infection in
cells that were infected with 2000 copies of XMRV. However,
none of the 33 plasma samples tested displayed visible fluorescence
signal even after 21 days post infection (Fig. 2D). The culture
supernatants were also negative for XMRV using both quantita-
tive PCR and RT-PCR (data not shown).
Discussion
The above results strongly support the conclusion that XMRV
and other MLV-related viruses are absent in healthy blood donors
in the population we studied. The rigorous testing employed and
use of highly sensitive PCR and cell culture methods to evaluate
the presence of both nucleic acid and infectious virus provide
strong evidence to support this conclusion. The failure to detect
XMRV in U.S. blood donor samples is unlikely due to the
sensitivity of PCR assays because they have been shown to be at
least as sensitive as those previously reported [22], and comparable
to those used by other labs enrolled in the assay evaluation study
sponsored by the Blood XMRV SRWG [21]. XMRV positive and
negative controls were correctly identified in both PCR and co-
culture experiments in our study indicating the accuracy of test
performance and validity of assay runs. In addition, the sample
size we tested was sufficiently large enough to potentially identify
at least 3–4 XMRV or MLV-related virus positive samples since
between 4–6% of healthy controls including blood donors were
reported to be positive for XMRV or MLV-like viruses in previous
studies conducted in the U.S. [2,6,19]. Therefore, based on testing
using highly sensitive detection assays we did not find evidence of
XMRV or MLV-related virus infection in the U.S. blood donor
samples we tested.
Our results are consistent with other recent findings that have
been reported in the U.S. Gao et al tested 425 plasma samples
from U.S. blood donors using a transcription mediated amplifi-
cation (TMA) assay and did not detect XMRV in these samples
[25]. Their assay was reported to be one of the most sensitive
assays in the assay evaluation study sponsored by the Blood
XMRV SRWG [21]. Qiu et al reported that only 0.1% of the U.S.
blood donors were positive for anti-XMRV antibodies by using
their prototype direct chemiluminescent immunoassays (CMIAs)
on the automated ARCHITECTH instrument for detecting anti-
XMRV assay, which is the first immunoassay that has been
evaluated by the well characterized XMRV infected animal bleeds
[26]. Switzer et al were unable to detect XMRV infection in 51
healthy controls and 43 U.S. blood donors using PCR and
serology assays [27]. Kunstman et al tested 996 samples from the
Chicago Multicenter AIDS Cohort Study (562 HIV-1 positive and
434 at high risk for HIV-1 infection, but HIV-1 negative
individuals), none of them were XMRV positive [28]. Henrich
et al were unable to detect XMRV infection in PBMC samples
from 43 HIV positive individuals, 97 rheumatoid arthritis patients,
26 transplant recipients and 95 general patients [29].
XMRV was also not or rarely detected in general populations
worldwide. Only about 1% of control groups were found to be
positive for XMRV in Germany [10], the U.K [12] and Japan
[30], but no XMRV was detected in Chinese blood donors [31].
Negative results were reported for XMRV testing of blood donors
or individuals infected HIV-1 in Africa [22]. These results indicate
Figure 1. PCR screening for XMRV or MLV-related virus. (A) PCR
products of 11 plasma samples (lane 1–11) collected in NIH Blood Bank
with XMRV gag gene primer pair. Lane 12 was positive control of XMRV.
(B) PCR products of 11 PBMC samples (lane 1–11) collected in the NIH
Blood Bank with XMRV gag gene primer pair. Lane 12 was positive
control of XMRV. (C) hGAPDH gene. Lane 1–11 was results for 11 PBMC
samples while lane 12 was positive control for hGAPDH.
doi:10.1371/journal.pone.0027391.g001
Table 1. Detection of XMRV in the plasma and PBMC samples
from the NIH Blood Bank
1.
Sample PCR results DERSE results
No. tested No. positive No. tested No. positive
Plasma 110 0 33 0
PBMCs 71 0 0 0
1Viral RNA isolated from plasma was analyzed for XMRV and HIV-1 using RT-
nested PCR while genomic DNA extracted from PBMCs was analyzed for XMRV
and HIV-1 using nested PCR and (q)PCR.
GAPDH was amplified in parallel as an internal control.
doi:10.1371/journal.pone.0027391.t001
Figure 2. GFP signal detection in DERSE cell culture. (A) Light
microscopy image for positive control. DERSE cells were infected with
culture supernatant from 22Rv1 cell. (B) Fluorescence microscopy image
for XMRV positive control. Panel C (light microscopy image) and D
(fluorescence microscopy image) for blood donor plasma in which no
XMRV was detected.
doi:10.1371/journal.pone.0027391.g002
Detection of XMRV in Blood Donors
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27391that XMRV or other MLV-like viruses may be very rare, or
absent in the general population overall. In contrast, our results
support the recent findings that the current positive detection of
XMRV or MLV-related virus in human samples may be due to
mouse DNA contamination rather than a true human infection.
Robinson et al reported that XMRV positive prostate cancer
tissues and 21.5% of XMRV negative cases were positive for
mouse IAP sequence [15]. Oakes et al found that by using a less
specific PCR assay, both XMRV and/or MLV were detected in
CFS patients. However, all positive samples were also positive for
mouse IAP while no contamination was observed in any of the
negative control samples [13]. Sato et al reported that endogenous
MLV was amplified in a commercial RT-PCR kit using standard
primers for XMRV [16]. The contamination originated from the
hybridoma cell line from which the monoclonal antibody used in
the polymerase reaction mixture to facilitate hot-start PCR was
prepared. Hue et al also demonstrated that XMRV specific
primers can amplify murine endogenous viral sequences [14].
These results indicate that mouse DNA contamination is
widespread and can confound XMRV detection in human
samples.
Furthermore, Hue et al compared the published XMRV
sequences with those from 22Rv1 cell, which is infected with
XMRV and found that the genetic distance among 22Rv1-derived
sequences exceeds that of patient-associated sequences, indicating
that patient-associated XMRV sequences are consistent with
laboratory contamination rather than a true human infection [14].
The 22Rv1 cell line was derived from a human prostate cancer
xenograft (CWR22) that was serially passaged in nude mice in
1990s. Interestingly, it was recently shown by Paprotka et al that
XMRV resulted from recombination between two endogenous
MLVs during passage of the CWR22 PC xenograft [17],
suggesting that the laboratory-derived virus may have contami-
nated samples for more than a decade and thereby contributed to
the inconsistent positive detection reported by various laboratories
that had used them for these studies and over extended periods of
time. The relevant published studies on XMRV and MLRV
findings in CFS, PCA and blood donors are listed in the Table S1.
In summary, we screened 110 plasma samples and 71 PBMC
samples collected from U.S. blood donors using well characterized
and highly sensitive PCR and culture assays. The testing employed
independent test operators and rigorous testing conditions aimed
at avoiding contamination. Under these conditions, none of the
samples were found to be positive for XMRV or MLV-related
virus sequences or infectious virus. Our results failed to
demonstrate the presence of XMRV or MLV-related viruses in
the samples we tested, and provide strong evidence for the absence
of XMRV or MLV-related virus in the U.S. blood donor
population we studied.
Supporting Information
Table S1 Relevant Published Studies on XMRV and
MLRV Findings in CFS, PCA and Blood Donors.
(DOC)
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